Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

IMpower133 (ClinicalTrials.gov identifier: NCT02763579), a randomized, double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-ligand 1 [PD-L1]) to carboplatin plus etoposide (CP/ET) for first-line (1L) treatment of extensive-stage small-cell lung cancer (ES-SCL...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Liu, Stephen V., Reck, Martin, Mansfield, Aaron S., Mok, Tony, Scherpereel, Arnaud, Reinmuth, Niels, Garassino, Marina Chiara, De Castro Carpeno, Javier, Califano, Raffaele, Nishio, Makoto, Orlandi, Francisco, Alatorre-Alexander, Jorge, Leal, Ticiana, Cheng, Ying, Lee, Jong-Seok, Lam, Sivuonthanh, McCleland, Mark, Deng, Yu, Phan, See, Horn, Leora
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2021
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078320/
https://ncbi.nlm.nih.gov/pubmed/33439693
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01055
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars